The compound attacks MRSA, C. diff, and several other deadly pathogens. Its discovery demonstrates the power of combining computational biology, genetic sequencing, and synthetic chemistry to study bacterial evolution.
A new study reveals how the drug fidaxomicin selectively targets a dangerous pathogen without causing harm to beneficial bacteria. The findings could inform the development of new narrow-spectrum antibiotics for treating other types of infection.
With a breadth and depth of experience across academia, the pharmaceutical industry, technology, healthcare, and the financial sector, this latest cohort of trustees brings new skill sets and perspectives to the community.